title: TNFα-mediated apoptosis in human osteoarthritic chondrocytes sensitized by PI3K-NF-κB inhibitor, not mTOR inhibitor.
abstract: To investigate apoptosis of osteoarthritic (OA) chondrocytes stimulated with different inhibitors targeting tumor necrosis factor-alpha (TNFα) pathway, we isolated first passage chondrocytes from OA patients and then treated them with the inhibitors in combination with TNFα, and then collected the stimulated chondrocytes for Western blotting. Chondrocytes from OA patients expressed cleaved caspase-3 and PARP, suggesting apoptotic background. We here, validated that 10 ng/ml of TNFα couldn't induce more chondrocytes apoptosis. PI3K inhibitor LY294002 or NF-κB inhibitor CAPE, but not mTOR inhibitor rapamycin and MEK1/2 inhibitor U0126 in combination with TNFα could facilitate apoptosis. CAPE-induced more apoptosis could be explained by c-FLIP downregulation more than cIAP1 upregulation. And, we showed the first time that PI3K-NF-κB pathway, but not mTOR pathway could prevent chondrocytes apoptosis induced by a pro-apoptotic factor TNFα and call for attention while trying to inhibit NF-κB as a therapeutic target.
authors.affiliation: Department of Orthopaedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuai Fu Yuan 1st, 100009 Beijing, Dongcheng, China.
authors.forename: Deling
authors.initials: D
authors.lastname: Li
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Wu
authors.forename: Yuanhui
authors.initials: Y
authors.lastname: Duan
authors.forename: Dongsheng
authors.initials: D
authors.lastname: Hao
authors.forename: Xinbo
authors.initials: X
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Luo
authors.forename: Baosheng
authors.initials: B
authors.lastname: Chen
authors.forename: Guixing
authors.initials: G
authors.lastname: Qiu
mesh_terms: D000368:Aged; D017209:Apoptosis / Q000187:drug effects*; D002070:Butadienes / Q000494:pharmacology; D002109:Caffeic Acids / Q000494:pharmacology; D053148:Caspase 3 / Q000032:analysis; D002478:Cells, Cultured; D019902:Chondrocytes / Q000187:drug effects*; D002867:Chromones / Q000494:pharmacology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D009570:Nitriles / Q000494:pharmacology; D010003:Osteoarthritis / Q000188:drug therapy*; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives / Q000494:pharmacology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000032:analysis; D020123:Sirolimus / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000502:physiology
chemical_list: D002070:Butadienes; D002109:Caffeic Acids; D002867:Chromones; D009025:Morpholines; D016328:NF-kappa B; D009570:Nitriles; D000081082:Phosphoinositide-3 Kinase Inhibitors; D014409:Tumor Necrosis Factor-alpha; C113580:U 0126; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D011065:Poly(ADP-ribose) Polymerases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; C505407:CASP3 protein, human; D053148:Caspase 3; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol; D020123:Sirolimus